Frontiers in Hematology

Frontiers Media S.A.

Journal websitePeer review: Peer review
Evaluation status available after sign-in

About the journal

Frontiers in Hematology is an open-access journal published by Frontiers Media S.A. in Switzerland, publishing in english. It is listed in DOAJ according to the sources read. Declared publication charge: 1,950 CHF. Declared review time at DOAJ: 15 weeks. Facts are reproduced as recorded at their sources with their capture dates; PublishLens indicators are available after sign-in.

Basic facts

Publisher
Frontiers Media S.A.
ISSN
2813-3935
Country
Switzerland
Languages
english
Access
Open access
Declared publication charge
1,950 CHF
Articles in DOAJ
163
Declared review time
15 weeks
Declared peer-review model
peer_review

Index listings

  • DOAJ · 2023-10-01
Indexing
DOAJ
APC
1,950 CHF
Declared review time (DOAJ)
15 weeks — journal-declared only (not measured)
Activity (OpenAlex)
Active — latest works 2026
PublishLens list status
Shown after sign-in
Counts for promotion at your university?
Choose your university and rank below ↓

Methodology signals (dated facts from their sources)

Details of the evaluation under the published methodology are shown to signed-in users (free).

Create a free account to view the evaluation

Journal profile

Descriptive metadata from public sources (DOAJ, OpenAlex, PubMed) as of the capture date shown — contains no assessment or judgment.

Articles in DOAJ

163

Most recent article

last month

Average review time (journal-declared via DOAJ)

15weeks

Works in OpenAlex

194

Last recorded publication year

2026

Reported by OpenAlex in 2 of 3 sources (CC0 flags, not verified indexing)DOAJSciELOOpenAlex Core

h-index

10

i10-index

12

From OpenAlex open data (CC0).

Editorial & policy12
Last DOAJ review date
2026-03-12
Added to DOAJ
2023-10-01
Declared plagiarism screening
Declared
Other fees beyond APC
No
Declared digital preservation
CLOCKSS
Observed digital preservation (Keepers registry)— snapshot 2026-10-05
CLOCKSS
Editorial board
Official page ↗
Open references deposited at Crossref
98%
ORCID iDs in current deposits
0%
Enrolled in Crossref Similarity Check
✓
Deposits licence metadata at Crossref
✓
APC waiver policy
View policy
Peer-review policy
View policy
Identity & continuity2
Source type
journal
NLM unique ID (PubMed)
9918697479006676
Classification2

Subjects (DOAJ)

Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens

LCC codes

RC254-282

Subject areas

  • Acute Myeloid Leukemia Research
  • Acute Myeloid Leukemia Research
  • Hemoglobinopathies and Related Disorders
  • Hemoglobinopathies and Related Disorders
  • Hematopoietic Stem Cell Transplantation
  • Hematopoietic Stem Cell Transplantation
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
Show all subjects (50)
  • CAR-T cell therapy research
  • CAR-T cell therapy research
  • Multiple Myeloma Research and Treatments
  • Multiple Myeloma Research and Treatments
  • Lymphoma Diagnosis and Treatment
  • Lymphoma Diagnosis and Treatment
  • Blood groups and transfusion
  • Blood groups and transfusion
  • Chronic Lymphocytic Leukemia Research
  • Iron Metabolism and Disorders
  • Acute Lymphoblastic Leukemia research
  • Chronic Lymphocytic Leukemia Research
  • Acute Lymphoblastic Leukemia research
  • Iron Metabolism and Disorders
  • Erythrocyte Function and Pathophysiology
  • Erythrocyte Function and Pathophysiology
  • Immune Cell Function and Interaction
  • Platelet Disorders and Treatments
  • Immune Cell Function and Interaction
  • Platelet Disorders and Treatments
  • Chronic Myeloid Leukemia Treatments
  • Chronic Myeloid Leukemia Treatments
  • Blood disorders and treatments
  • Blood disorders and treatments
  • Eosinophilic Disorders and Syndromes
  • Eosinophilic Disorders and Syndromes
  • Viral-associated cancers and disorders
  • Virus-based gene therapy research
  • Protein Degradation and Inhibitors
  • Viral-associated cancers and disorders
  • Protein Degradation and Inhibitors
  • Virus-based gene therapy research
  • Hematological disorders and diagnostics
  • T-cell and B-cell Immunology
  • Phagocytosis and Immune Regulation
  • Autoimmune and Inflammatory Disorders Research
  • T-cell and B-cell Immunology
  • Phagocytosis and Immune Regulation
  • Autoimmune and Inflammatory Disorders Research
  • Parvovirus B19 Infection Studies
  • Childhood Cancer Survivors' Quality of Life
  • Childhood Cancer Survivors' Quality of Life

Keywords (DOAJ)

  • hematology
  • haematological tumours
  • genetic immunology
  • stem cells
  • cancer therapy

Community confirmations — what users saw in MJL or Scopus Sources; not platform verification and never part of any score.

Loading community confirmations…
How do we evaluate?Publisher of this journal? Appeal a derived assessment or request a factual correction

The journal's record in other sources:Web of Science MJLDOAJ

Everything shown here is produced automatically from named sources (DOAJ, OpenAlex, Crossref, PubMed, the Norwegian register) as of its capture date, with no human editing. Facts appear as recorded at the source; derived scores (PCI, PTD, PublishLens score) follow a published methodology. Not a judgement on the journal, not an official accreditation, not advice.

Wrong items are corrected automatically by re-reading the source (24 h for daily sources, 7 days for weekly ones) with a dated change log, and each item links to its source record. PublishLens-derived assessments are contested through the appeals mechanism (15 working days). Appeals · Indicator guide

Norwegian register data: Kanalregisteret (HK-dir, Norway) — CC BY 4.0 / NLOD — adapted: level extracted per year · OASPA member list — CC BY

Last automated source read: